PortfoliosLab logoPortfoliosLab logo
MIRA vs. BMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MIRA vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MIRA Pharmaceuticals Inc. Common Stock (MIRA) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MIRA achieves a -47.55% return, which is significantly lower than BMY's 25.17% return.


MIRA

1D
-2.98%
1M
-16.17%
6M
-36.13%
YTD
-47.55%
1Y
-48.57%
3Y*
5Y*
10Y*
ALL TIME*
-51.72%

BMY

1D
0.69%
1M
12.35%
6M
21.21%
YTD
25.17%
1Y
54.75%
3Y*
6.92%
5Y*
3.38%
10Y*
2.16%
ALL TIME*
9.43%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$711.50M$665.03M$681.59M
$48.29K$55.07K$96.54K

MIRA vs. BMY - Yearly Performance Comparison


2026 (YTD)202520242023
MIRA
MIRA Pharmaceuticals Inc. Common Stock
-47.55%32.46%8.57%-85.00%
BMY
Bristol-Myers Squibb Company
25.17%0.11%15.81%-16.06%

Correlation

The correlation between MIRA and BMY is 0.07, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.07

Correlation (All Time)
Calculated using the full available price history since Aug 3, 2023

0.09

Fundamentals

Market Cap

MIRA:

$33.28M

BMY:

$133.37B

EPS

MIRA:

-$1.47

BMY:

$4.54

Total Revenue (TTM)

MIRA:

$0.00

BMY:

$49.19B

Gross Profit (TTM)

MIRA:

$0.00

BMY:

$34.51B

EBITDA (TTM)

MIRA:

-$6.93M

BMY:

$16.67B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MIRA vs. BMY — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

MIRA
MIRA Risk / Return Rank: 99
Overall Rank
MIRA Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
MIRA Sortino Ratio Rank: 1111
Sortino Ratio Rank
MIRA Omega Ratio Rank: 1313
Omega Ratio Rank
MIRA Calmar Ratio Rank: 66
Calmar Ratio Rank
MIRA Martin Ratio Rank: 44
Martin Ratio Rank

BMY
BMY Risk / Return Rank: 9292
Overall Rank
BMY Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
BMY Sortino Ratio Rank: 9393
Sortino Ratio Rank
BMY Omega Ratio Rank: 9090
Omega Ratio Rank
BMY Calmar Ratio Rank: 9494
Calmar Ratio Rank
BMY Martin Ratio Rank: 9292
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

MIRA vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MIRA Pharmaceuticals Inc. Common Stock (MIRA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MIRABMYDifference
Sharpe ratioReturn per unit of total volatility

-2.86

Sortino ratioReturn per unit of downside risk

-4.18

Omega ratioGain probability vs. loss probability

0.88

1.36

-0.48

Calmar ratioReturn relative to maximum drawdown

-0.93

4.66

-5.59

Martin ratioReturn relative to average drawdown

-1.61

11.09

-12.70

MIRA vs. BMY - Sharpe Ratio Comparison

The current MIRA Sharpe Ratio is -0.71, which is lower than the BMY Sharpe Ratio of 2.14. The chart below compares the historical Sharpe Ratios of MIRA and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MIRA vs. BMY - Drawdown Comparison

The maximum MIRA drawdown since its inception was -92.69%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for MIRA and BMY.


Loading charts...

Drawdown Indicators


MIRABMYDifference

Max Drawdown

Largest peak-to-trough decline

-92.69%

-72.03%

-20.66%

Max Drawdown (1Y)

Largest decline over 1 year

-56.00%

-12.53%

-43.47%

Max Drawdown (3Y)

Largest decline over 3 years

-92.34%

-34.11%

-58.23%

Max Drawdown (5Y)

Largest decline over 5 years

-47.67%

Max Drawdown (10Y)

Largest decline over 10 years

-47.67%

Current Drawdown

Current decline from peak

-89.33%

-4.95%

-84.38%

Average Drawdown

Average peak-to-trough decline

-78.76%

-22.36%

-56.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

32.46%

5.25%

+27.21%

Volatility

MIRA vs. BMY - Volatility Comparison

MIRA Pharmaceuticals Inc. Common Stock (MIRA) has a higher volatility of 11.44% compared to Bristol-Myers Squibb Company (BMY) at 9.10%. This indicates that MIRA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MIRABMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.44%

9.10%

+2.34%

Volatility (6M)

Calculated over the trailing 6-month period

47.16%

19.64%

+27.52%

Volatility (1Y)

Calculated over the trailing 1-year period

73.32%

27.86%

+45.46%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

385.18%

24.49%

+360.69%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

385.18%

25.46%

+359.72%

Dividends

MIRA vs. BMY - Dividend Comparison

MIRA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 3.84%.


PositionTTM20252024202320222021202020192018201720162015
BMY
Bristol-Myers Squibb Company
3.84%4.60%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%
MIRA
MIRA Pharmaceuticals Inc. Common Stock
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

MIRA vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between MIRA Pharmaceuticals Inc. Common Stock and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


MIRA and BMY have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MIRA has higher volatility (11.44%) compared to BMY (9.10%). In terms of maximum drawdown, MIRA dropped -92.69% vs BMY's -72.03%.

BMY currently has the higher Sharpe Ratio (2.14 vs -0.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MIRA and BMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer